Table 4.

Univariate analysis of 2-year clinical outcomes

	RI	NRM	LFS	OS	GRFS	aGVHD grade II–IV	aGVHD grade III–IV	cGVHD	ext. cGVHD
MSD	31.6% [29.2–34%]	13% [11.4–14.7%]	55.4% [52.8–57.9%]	67.4% [64.8–69.8%]	39% [36.4–41.5%]	28.9% [26.8–31.1%]	10.5% [9.1–12%]	38.8% [36.3–41.3%]	19.5% [17.5–21.7%]
Haplo	26% [21.5–30.8%]	22.9% [18.8–27.3%]	51% [45.7–56.2%]	58.8% [53.3–63.9%]	40.6% [35.4–45.7%]	36.3% [31.5–41.1%]	15.2% [11.9–19%]	32% [27.1–37.1%]	11.9% [8.6–15.8%]
p	0.017	0.001	0.07	0.001	0.74	0.002	0.005	0.009	0.001

RI, relapse incidence; NRM, non-relapse mortality; LFS, leukemia-free survival; OS, overall survival; GVHD, graft versus host disease; GRFS, GVHD-free/relapse-free survival; KPS, Karnofsky performance status; ATG, anti-thymocyte globulin; PTCy, post-transplant cyclophosphamide; RIC, reduced intensity conditioning; MAC, myeloablative conditioning; PB, peripheral blood; BM, bone marrow